<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912570</url>
  </required_header>
  <id_info>
    <org_study_id>YIG0502101</org_study_id>
    <nct_id>NCT04912570</nct_id>
  </id_info>
  <brief_title>Thrombus Aspiration in Heavy Thrombus Burden Acute ST-elevation Myocardial Infarction</brief_title>
  <acronym>TSUNAMI</acronym>
  <official_title>Thrombus Aspiration in Heavy Thrombus Burden Acute ST-elevation Myocardial Infarction: TSUNAMI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Young Investigator Group of Cardiovascular Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Young Investigator Group of Cardiovascular Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent guidelines for the management of ST-elevation myocardial infarction (STEMI) recommend&#xD;
      against the routine use of thrombus aspiration (TA) during primary percutaneous coronary&#xD;
      intervention (PPCI) (Class III indication). Yet, so far, there is limited data regarding its&#xD;
      role STEMI patients with heavy thrombus burden (TB).&#xD;
&#xD;
      The aim of this trial is to evaluate the effects of manual TA and PCI in comparison to&#xD;
      conventional PCI alone in a real-life clinical trial among heavy TB STEMI patients undergoing&#xD;
      PPCI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent guidelines for the management of ST-elevation myocardial infarction (STEMI) recommend&#xD;
      against the routine use of thrombus aspiration (TA) during primary percutaneous coronary&#xD;
      intervention (PPCI) (Class III indication). Yet, so far, there is limited data regarding its&#xD;
      role in STEMI patients with heavy thrombus burden (TB).&#xD;
&#xD;
      The aim of this trial is to evaluate the effects of manual TA and PCI in comparison to&#xD;
      conventional PCI alone in a real-life clinical trial among heavy TB STEMI patients undergoing&#xD;
      PPCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic results</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>Successful revascularization assessed by TIMI flow</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Angiographic results</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>Successful revascularization assessed by myocardial blush.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Angiographic results</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>Successful revascularization assessed by ST-segment resolution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In-hospital Major adverse cerebrovascular and cardiovascular events (MACCE)</measure>
    <time_frame>10 days</time_frame>
    <description>Incidence of any major adverse cerebrovascular and cardiovascular events which includes: death (either all-cause or cardiac), nonfatal myocardial infarction, stroke and revascularization (with optional additional specification of target vessel or lesion, i.e., if the revascularization occurred at the site of a previously identified diseased coronary vessel or atherosclerotic lesion, respectively)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short term Major adverse cerebrovascular and cardiovascular events (MACCE)</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of any major adverse cerebrovascular and cardiovascular events which includes: death (either all-cause or cardiac), nonfatal myocardial infarction, stroke and revascularization (with optional additional specification of target vessel or lesion, i.e., if the revascularization occurred at the site of a previously identified diseased coronary vessel or atherosclerotic lesion, respectively) in the period of 6 months after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety outcomes</measure>
    <time_frame>10 days</time_frame>
    <description>Incidence of any bleeding that may be encountered during the hospital stay after randomization. (Major or Minor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Hospital Heart failure status</measure>
    <time_frame>10 days</time_frame>
    <description>Incidence of any event of heart failure that may be encountered during the hospital stay after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short term Hospitalization due to heart failure</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of any event of heart failure that may be encountered during any other re-admission due to a &quot;heart failure&quot; diagnosis up to 6 months after randomization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Manual Thrombus Aspiration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Manual Thrombus aspiration in STEMI patients with Heavy thrombus burden (TIMI 0-1 or TB classification 4-5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional PCI according to the most recent guidelines in STEMI patients with no heavy thrombus burden (TIMI 0-1 or TB classification 4-5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Manual Thrombus Aspiration</intervention_name>
    <description>Manual thrombus aspiration using one of the FDA approved aspirators will be done.</description>
    <arm_group_label>Manual Thrombus Aspiration</arm_group_label>
    <other_name>Thrombus Aspiration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard PCI</intervention_name>
    <description>Standard PCI according to the most recent guidelines</description>
    <arm_group_label>Standard PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  STEMI patients with heavy thrombus burden as assessed by TIMI score of 0-1 or thrombus&#xD;
             burden classification 4-5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  STEMI patients with low thrombus burden (TIMI 2-3 or TB 0-3)&#xD;
&#xD;
          -  History of hypersensitivity or allergy to any of the study drugs, as well as known or&#xD;
             suspected contraindications to the study drugs.&#xD;
&#xD;
          -  Symptomatic hypotension and/or an SBP &lt; 100 mmHg at the time of randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haitham Badran, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University - Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmoud H Abdelnabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alexandria - Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed M El Amrawy, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alexandria - Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yasser Sadek, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Heart Institute, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud H Abdelnabi, MD</last_name>
    <phone>+201007573530</phone>
    <email>mahmoud.hassan.abdelnabi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdallah M Almaghraby, MSc</last_name>
    <email>dr.maghraby@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Andalusia Hospitals</name>
      <address>
        <city>Alexandria</city>
        <zip>21521</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Haitham Badran, MD</last_name>
      <email>Haithamcardiology@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Abdallah Almaghraby, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Cardiac Center (ICC)</name>
      <address>
        <city>Alexandria</city>
        <zip>21524</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Ahmed El Amrawy, MD</last_name>
      <phone>+201006222922</phone>
      <email>dr.ahmed.elamrawy@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ahmed M El Amrawy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Naguib, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ain Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Haitham Badran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Heart Institute</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Yasser Sadek, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

